General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Stocks Churn as Traders Waver on US Rates Outlook: Markets Wrap | news.google.com • |
Microsoft Stock Outlook: Is MSFT a Millionaire-Maker AI Play to Make? | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Franca, i think you meant to say $20 plus by May 27th. I think you you will find most analystswould agree that with approval $60-100 is more likely by end of year. Unlike other medications coming to market we already have a built in market already worth billions. This is a wholly unique opportunity that doesn’t come around very often if ever
Saltytimtation- off label gets no protection. The new medication will be pure and of standardized strength/potency. There will be no one wiling to compound off-label because of patent infringement. No providers will write off label for fear of medical malpractice. Insurance companies will not pay for it or insure providers that write it. To put it simple that even with the price increase.… this will be the cheapest and safest treatment available. Compounding off label will no longer exist which means 100% capture of that market.
Short ratio has grown from .68 to 3.24. Day traders and shorts are playing with the price, do not be fooled. This is truly not the accurate (future) price of this stock…. The 28th of May is near. Keep the faith. Any day is a possible approval…. I would be a nervous Nelly if I was trading short.
It may be that the system is capable of beating this one down… so it is doing it. Remember EMA and FDA want this medication approved so it stops: compounding, impurities, particulates, and lack of drug potency. I appreciate/capitalizing on the bargain pricing.
Old news and already built into the price.
Frank, you selling short only creates shares you will have to cover later. When you are done in the kiddy sand box.… come play with the real investors. Price doesn't reflect value at this time.
The current price does not reflect its value. It is simply a reflection of daytraders and shorts upon the approval of EMA revenue will begin to be produced and an entirely different class of investor will be coming to the stock. Which point price corrections will begin to accelerate forward based on prebuilt market, and future revenues.
Syntone Ventures LLC is a major pharma distributor in the EU……just a little foreshadowing of things to come!
Waldo_III, that is your dumbest post yet. Hard to treat you like an experienced investor.
Let’s be “Frank”. First of all, no thanks!! Agitators are better suited for washing machines. “Short sided” traders will be taken to the cleaners soon. However their soiled under garments will be hard to clean. The final count down is near….$60 dollars by year’s end!
Frank, you keep saying garbage, but after all these years, you’re still here try to explain that one to us
Frank ~ go educate yourself. No one wants to read your outlandish statements. we prefer to deal with people that work in facts.
Just another day of shorts selling to shorts. True ling investors have not lost any money. True longs don't gamble on emotional daily swings. The real money is in bringing this product to market. Today's price diesnotvreforct the real value. Be patient and hold, approval is only days away.
I just bought me some more shares from a crazy short. I sure love getting good deals.
Isn't interesting how the shorts can always find a buyer at this price. I wonder if they think there will be sellers when the EU approval comes in a few days… like France Chance said it will be a lot of easy money for the longs. Sorry shorts you arecraking one to many rounds on the dance floor. You are going to play the fiddler his due.